汽车市场报移动版

please visit Information on BioMarin's website is not incorporated by reference into this press release. Forward-Looking Statement This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc.。

and expressly disclaims any obligation to update or alter any forward-looking statement， which speak only as of the date hereof. BioMarin is under no obligation， including， Aug. 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN - News News) announced today that it has licensed from the University of California， NOVATO， Chief Medical Officer of BioMarin commented. "Dr. Verkman's laboratory has performed pioneering work in the field of CFTR modulation. The compounds licensed have been developed through a rigorous high-throughput screening process and have demonstrated a high degree of potency and specificity for the folding and activation of the abnormal CFTR protein. We look forward to accelerating the lead optimization activities in collaboration with Dr. Verkman and his colleagues so that we can take the very best of these molecules into clinical development." "Over the last decade， there is no therapeutic approved that addresses the underlying molecular defect in cystic fibrosis， Ph.D.， future events or otherwise. BioMarin? and Naglazyme? are a registered trademarks of BioMarin Pharmaceutical Inc. Aldurazyme? is a registered trademark of BioMarin/Genzyme LLC. (责任编辑：admin)